Skip to main content

CSL share price lifts on HY23 results | CSL Limited (ASX:CSL)

Sophia Mavridis
February 14, 2023

Biotherapeutics company, CSL Limited (ASX:CSL), reported its half year earnings today, beating forecasts, and the market has responded positively.

For the six months, CSL reported a 19% increase in revenue to US$7,183 million, as well as a 10% lift in net profit after tax before amortisation in constant currency to US$1,957 million. Citi were expecting NPAT of US$1,795 million.

CSL’s earnings were partly driven by a five-month contribution from Vifor Pharma, as well as impressive sales growth and record levels of plasma collections.

CSL have lifted its interim dividend by 2.9% to US$1.07 per share.

And management reaffirmed its guidance for FY2023 NPAT in the range of US$2.7 billion to US$2.8 billion at constant currency.

CSL’s share price has been on the rise today, currently trading 0.6% higher at AU$306.88, at the time of recording.

Morning Bell 18 January

Paulina Peters
January 18, 2022

Morning Bell 17 January

Sophia Mavridis
January 17, 2022

Weekly Wrap 14 January

Sophia Mavridis
January 14, 2022

Morning Bell 13 January

Paulina Peters
January 13, 2022

Morning Bell 12 January

Sophia Mavridis
January 12, 2022

Morning Bell 11 January

Paulina Peters
January 11, 2022

Morning Bell 10 January

Sophia Mavridis
January 10, 2022

Thank you & see you in 2022

Sophia Mavridis
December 21, 2021

Morning Bell 17 December

Sophia Mavridis
December 17, 2021

Morning Bell 16 December

Paulina Peters
December 16, 2021

Morning Bell 15 December

Sophia Mavridis
December 15, 2021

Morning Bell 14 December

Paulina Peters
December 14, 2021